Amenorrhea News and Research RSS Feed - Amenorrhea News and Research

Amenorrhea is the absence of a menstrual period. Primary amenorrhea is when a young woman has not yet had a period by age 16. Secondary amenorrhea describes someone who used to have a regular period but then it stopped for at least three months (this can include pregnancy).
New guidelines on management and return to play of Female Athlete Triad discussed at AMSSM

New guidelines on management and return to play of Female Athlete Triad discussed at AMSSM

The Female Athlete Triad is a medical condition often observed in physically active girls and women, and involves three components: low energy availability with or without disordered eating, menstrual dysfunction and low bone mineral density. [More]

TherapeuticsMD's fourth quarter 2013 net revenue increases to $2.9 million

TherapeuticsMD, Inc., a women's healthcare company, today announced results for the three-month period and full-year ended December 31, 2013. [More]
TherapeuticsMD starts TX 12-002-HR phase 3 clinical trial for secondary amenorrhea

TherapeuticsMD starts TX 12-002-HR phase 3 clinical trial for secondary amenorrhea

TherapeuticsMD, Inc., a women's healthcare company, announced today that it has initiated the SPRY Trial, a randomized, placebo-controlled phase 3 clinical trial designed to evaluate the safety and efficacy of TX 12-002-HR, its oral progesterone candidate for secondary amenorrhea, a condition treated to maintain fertility in young premenopausal women. [More]
Bisphosphonate zoledronate treatment not effective in women with chemoresistant breast cancer

Bisphosphonate zoledronate treatment not effective in women with chemoresistant breast cancer

Treatment with the bisphosphonate zoledronate did not improve outcomes for women with chemoresistant breast cancer, according to initial results of a phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. [More]

Research report on bone densitometers market

According to a new market report published by Transparency Market Research "Bone Densitometers Market(DEXA, QCT, pDEXA, SEXA, pQCT, RA and QUS)- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global bone densitometers market was valued at USD 777.9 million in 2012 and is expected to grow at a CAGR of 3.3% from 2013 to 2019, to reach an estimated value of USD 908.5million in 2019. [More]
Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. today announced that the company is acquiring exclusive rights in the United States for Saphris (asenapine) sublingual tablets, a treatment for adult patients with schizophrenia or acute bipolar mania, from Merck Sharp & Dohme B.V., a wholly owned subsidiary of Merck & Co., Inc. [More]

Women diagnosed for menopause after breast cancer may vary with type of doctors

Hormonal treatment for breast cancer causes menopause in over 80% of women in the first year of therapy, but now new research, published in the peer-reviewed journal Climacteric, has found that how these women are diagnosed and treated for menopausal symptoms can vary substantially according to which type of doctor a woman sees. [More]
FDA accepts Sunovion’s two LATUDA sNDAs for review

FDA accepts Sunovion’s two LATUDA sNDAs for review

Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental New Drug Applications (sNDAs) for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression). [More]
GnRH agonist may protect breast cancer patient fertility

GnRH agonist may protect breast cancer patient fertility

Treatment with a gonadotropin-releasing hormone agonist may reduce the risk for chemotherapy-induced amenorrhea, research shows. [More]

IOF review outlines pathophysiology, diagnosis and management of osteoporosis in young adults

Much of the research defining osteoporosis and fracture risk has focused on older adults, i.e. postmenopausal women and men over the age of 50. While older adults are at highest risk of osteoporosis and related fractures, the disease can also affect younger adults between 20 and 50 years of age. However, the diagnosis and management of osteoporosis in young adults is complicated by special challenges, including a complex pathophysiology and the related fact that there is no clear definition of osteoporosis, or of intervention thresholds, in this age group. [More]
Study finds some possible shortfalls in screening methods for female athlete triad

Study finds some possible shortfalls in screening methods for female athlete triad

Female athletes, particularly those involved in high level college sports at the NCAA Division I level, are particularly prone to a trio of medical issues called the "female athlete triad." A new study conducted by sports medicine researchers at the Medical College of Wisconsin found there are some possible shortfalls in the methods used to screen these athletes for the triad, and that could put athletes at risk for lifelong health problems. [More]
Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion Pharmaceuticals Inc. today announced results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to LATUDA. [More]
Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone). [More]
FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of adult patients with kidney tumors known as renal angiomyolipomas and tuberous sclerosis complex (TSC), who do not require immediate surgery. [More]

Watson introduces generic PROMETRIUM for endometrial hyperplasia

Watson Pharmaceuticals, Inc. today confirmed that Watson has launched an authorized generic version of PROMETRIUM (progesterone, USP) Capsules 100mg and 200mg, as part of an agreement with Abbott Laboratories. [More]
Influenza shot boosts immune response in pregnant women, protects neonatal babies

Influenza shot boosts immune response in pregnant women, protects neonatal babies

The researchers studied the immune response of 107 pregnant women after they were injected with a single dose of non-adjuvant H1N1 vaccine. They concluded that the influenza shot boosted the immune response in pregnant women and at the same time protected neuronatal babies via the antibodies that transferred through the placenta. [More]

Study: Women still have hot flushes/night sweats years after menopause

Women still have hot flushes and night sweats years after the menopause finds a new study published today in BJOG: An International Journal of Obstetrics and Gynaecology. [More]
Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors. [More]
Long-term effects of chemotherapy on women's reproductive health

Long-term effects of chemotherapy on women's reproductive health

Current estimates of the impact of chemotherapy on women's reproductive health are too low, according to a University of California, San Francisco (UCSF) study. [More]
Smoking, social class may lead to POF in women

Smoking, social class may lead to POF in women

POF is not only associated with infertility but also with significantly increased morbidity and mortality, as well as a decreased quality of life equivalent to that of people with type 2 diabetes or rheumatoid arthritis, said Dr. Rumana Islam, from Imperial College, London, UK. [More]